ReviewExploration of targeted anti-tumor therapy2025

Strategies to overcome resistance to enfortumab vedotin and pembrolizumab for patients with urothelial carcinoma: harnessing present knowledge for future advances.

Albert Jang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.